Regenxbio (NASDAQ: RGNX) revenue
Regenxbio reported revenue of $170.4m for fiscal 2025, 104.5% more than in fiscal 2024 ($83.3m). Since fiscal 2016 its revenue has grown by 3,614.1%, an average growth of 49.4% a year.
Regenxbio's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2019, −83.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $170.4m | +104.5% | −$161.2m | −94.6% |
| 2024 | $83.3m | −7.7% | −$233.3m | −280.0% |
| 2023 | $90.2m | −19.9% | −$268.1m | −297.1% |
| 2022 | $112.7m | −76.0% | −$262.9m | −233.2% |
| 2021 | $470.3m | +204.3% | $160.0m | 34.0% |
| 2020 | $154.6m | +338.7% | −$119.2m | −77.1% |
| 2019 | $35.2m | −83.9% | −$149.0m | −422.9% |
| 2018 | $218.5m | +2,002.4% | $88.1m | 40.3% |
| 2017 | $10.4m | +126.5% | −$75.9m | −730.2% |
| 2016 | $4.6m | — | −$65.3m | −1,423.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Regenxbio revenue compared with its sector
By revenue for its latest fiscal year, Regenxbio ranks 257th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Regenxbio, 104.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 255th | Phathom Pharmaceuticals | $175.1m | 216.9% |
| 256th | Syndax Pharmaceuticals | $172.4m | 627.8% |
| 257th | Regenxbio | $170.4m | 104.5% |
| 258th | Ginkgo Bioworks | $170.2m | −25.1% |
| 259th | Pacific Biosciences of California | $160.0m | 3.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Regenxbio
- How much revenue did Regenxbio make in fiscal 2025?
- Regenxbio reported revenue of $170.4m for fiscal 2025, compared with $83.3m in fiscal 2024.
- How much has the revenue of Regenxbio grown?
- Between fiscal 2016 and fiscal 2025 it went from $4.6m to $170.4m: 3,614.1% more, an average growth of 49.4% a year.
- What was the best year for revenue at Regenxbio?
- Of its last 10 fiscal years, fiscal 2021, with $470.3m.
- Where does Regenxbio rank in its sector by revenue?
- It ranks 257th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Regenxbio come from?
- From the annual report (Form 10-K) that Regenxbio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Regenxbio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Regenxbio: the Regenxbio page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.